Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
Teijin Pharma is poised to gradually shift its focus away from the areas of bone and joint disorders and metabolic and cardiovascular diseases to the specialty field of rare and intractable illnesses, the company’s incoming president told Jiho. The strategy…
To read the full story
Related Article
- Teijin Still Seeking “Best Owner” for Legacy Drug Portfolio
August 5, 2026
- Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
June 18, 2026
- Teijin to Offload Legacy Drug Portfolio as It Speeds Up Pivot to Rare Diseases
May 12, 2026
- Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
- Teijin Pharma Picks R&D Chief Taneda for President from April
February 7, 2023
BUSINESS
- Keytruda Holds Top Spot for 35th Straight Month in August: Encise
September 7, 2026
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…